健玛博

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $40 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Wolfe Research Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• TD Cowen Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $43
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  Wells Fargo Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $58
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Truist Financial Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/6/30
• Truist Financial Maintains Genmab(GMAB.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  William Blair Maintains Genmab(GMAB.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $35 to $43
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)
  TipRanks · 2026/8/12
• 评级变动
  TD Cowen Upgrades Genmab(GMAB.US) to Buy Rating, Raises Target Price to $43
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/2
• 评级变动
  Truist Financial Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/27
• 评级变动
  TD Cowen Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $54
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  William Blair Maintains Genmab(GMAB.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/26
• 评级变动
  Wolfe Research Initiates Genmab(GMAB.US) With Buy Rating, Announces Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/3/27
• 评级变动
  H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $38
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 评级变动
  Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Cuts Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/5/8

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。